Cargando…

Dynamic Changes in the Levels of Amyloid-β(42) Species in the Brain and Periphery of APP/PS1 Mice and Their Significance for Alzheimer’s Disease

Although amyloid-β(42) (Aβ(42)) has been used as one of the core biomarkers for Alzheimer’s disease (AD) diagnosis, the dynamic changes of its different forms in the brain, blood, and even intestines and its correlation with the progression of AD disease remain obscure. Herein, we screened Aβ(42)-sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Liding, Yang, Changwen, Li, Yanqing, Niu, Shiqi, Liang, Xiaohan, Zhang, Zhihong, Luo, Qingming, Luo, Haiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430227/ https://www.ncbi.nlm.nih.gov/pubmed/34512259 http://dx.doi.org/10.3389/fnmol.2021.723317

Ejemplares similares

Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain Aβ burden and improves olfactory dysfunction of APP/PS1 mice by nasal delivery
por: Liu, Ni, et al.
Publicado: (2022)

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer’s disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay
por: Zhang, Liding, et al.
Publicado: (2023)

Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
por: Zhang, Liding, et al.
Publicado: (2021)

Elevated Plasma Oligomeric Amyloid β-42 Is Associated with Cognitive Impairments in Cerebral Small Vessel Disease
por: Qu, Wensheng, et al.
Publicado: (2023)

Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism
por: Liu, Ni, et al.
Publicado: (2022)

Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease
por: Xiang, Yang, et al.
Publicado: (2015)

Memory deficiency, cerebral amyloid angiopathy, and amyloid-β plaques in APP+PS1 double transgenic rat model of Alzheimer’s disease
por: Klakotskaia, Diana, et al.
Publicado: (2018)

Klotho overexpression improves amyloid‐β clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease
por: Zhao, Yue, et al.
Publicado: (2020)

Dampened Slow Oscillation Connectivity Anticipates Amyloid Deposition in the PS2APP Mouse Model of Alzheimer’s Disease
por: Leparulo, Alessandro, et al.
Publicado: (2019)

Neurogenesis, Neurodegeneration, Interneuron Vulnerability, and Amyloid-β in the Olfactory Bulb of APP/PS1 Mouse Model of Alzheimer's Disease
por: De la Rosa-Prieto, Carlos, et al.
Publicado: (2016)

Information on antiprotonic atoms and the nuclear periphery from the PS209 experiment
por: Trzcinska, A., et al.
Publicado: (2001)

Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide
por: Zhang, Jian-Xiang, et al.
Publicado: (2019)

VIP Enhances Phagocytosis of Fibrillar Beta-Amyloid by Microglia and Attenuates Amyloid Deposition in the Brain of APP/PS1 Mice
por: Song, Min, et al.
Publicado: (2012)

Advances in Amyloid-β Clearance in the Brain and Periphery: Implications for Neurodegenerative Diseases
por: Ullah, Rahat, et al.
Publicado: (2023)

Anodal Transcranial Direct Current Stimulation Can Improve Spatial Learning and Memory and Attenuate Aβ(42) Burden at the Early Stage of Alzheimer’s Disease in APP/PS1 Transgenic Mice
por: Luo, Yinpei, et al.
Publicado: (2020)

Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice
por: Dickey, Chad A, et al.
Publicado: (2005)

Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery
por: Mosconi, Lisa, et al.
Publicado: (2017)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
por: Carrera, Iván, et al.
Publicado: (2013)

Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
por: Carrera, Ivan, et al.
Publicado: (2014)

Cyclic Glycine-Proline Improves Memory and Reduces Amyloid Plaque Load in APP/PS1 Transgenic Mouse Model of Alzheimer's Disease
por: Arora, Tushar, et al.
Publicado: (2023)

Icaritin, an inhibitor of beta-site amyloid cleaving enzyme-1, inhibits secretion of amyloid precursor protein in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway
por: Feng, Fei, et al.
Publicado: (2019)

Navβ2 knockdown improves cognition in APP/PS1 mice by partially inhibiting seizures and APP amyloid processing
por: Hu, Tao, et al.
Publicado: (2017)

Cryo‐electron Microscopy Imaging of Alzheimer's Amyloid‐beta 42 Oligomer Displayed on a Functionally and Structurally Relevant Scaffold
por: Wu, Jinming, et al.
Publicado: (2021)

SRC-1 Knockout Exerts No Effect on Amyloid β Deposition in APP/PS1 Mice
por: Wu, Qiong, et al.
Publicado: (2020)

Allosteric Modulation of PS1/γ-Secretase Conformation Correlates with Amyloid β(42/40) Ratio
por: Uemura, Kengo, et al.
Publicado: (2009)

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
por: Zhang, Yuan, et al.
Publicado: (2019)

Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model
por: Meilandt, William J., et al.
Publicado: (2020)

Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?
por: Mossello, Enrico, et al.
Publicado: (2010)

Correction: Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery
por: Mosconi, Lisa, et al.
Publicado: (2018)

Could Alzheimer’s Disease Originate in the Periphery and If So How So?
por: Morris, Gerwyn, et al.
Publicado: (2018)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice
por: Wang, Jun, et al.
Publicado: (2020)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
por: Rosenberry, Terrone L., et al.
Publicado: (2022)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
por: Zaretsky, Dmitry V., et al.
Publicado: (2022)

DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease
por: Sha, Sha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e9nec055rrhe65mi9t729jeevf